NKTR

Dapirolizumab Pegol

Systemic lupus erythematosus (SLE)

Phase 3

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

Potential Catalyst Date

  • TBD


Clinical Trial

  • NCT04294667: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • NCT02804763: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus


Related Links


Prior Work/Results



HC updated 5/27/20

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon